Cabometyx becomes the first systemic therapy approved in EU for advanced neuroendocrine tumours

In an unprecedented stride in cancer treatment, the pharmaceutical company Ipsen’s drug Cabometyx has been approved by the European Commission for treating advanced neuroendocrine tumors. This marks Cabometyx as the first and only systemic therapy to achieve such a standing within the European Union.

Neuroendocrine tumors develop slowly and can originate in various parts of the body, necessitating multiple lines of therapy as the disease advances. A lack of options upon disease progression and the necessity for tailored treatments pose significant challenges. Indeed, no approved treatment options existed for 27% of patients diagnosed with lung NET until now.

Cabometyx has shown promising results in the CABINET Phase III trial, showcasing a significant reduction in the risk of disease progression or death. The approval of Cabometyx offers a glimpse of hope into this complex area of medical science, offering a unique and simplified treatment option where few to none previously existed.

The approval of Cabometyx comes on the back of data derived from the CABINET Phase III trial. The trial investigated the impact of Cabometyx against a placebo in patients with advanced pNETs or epNET whose diseases had advanced after prior systemic therapy. Outcomes have been overwhelmingly in favor of Cabometyx, significantly optimizing the progression-free survival rate.